Screener
Celldex Therapeutics CLDX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's debt-to-equity?
- Celldex Therapeutics (CLDX) reported debt-to-equity of 0× in Q2 2026.
- How has Celldex Therapeutics's debt-to-equity changed year-over-year?
- Celldex Therapeutics's debt-to-equity increased by 50.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Celldex Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Celldex Therapeutics's debt-to-equity has grown at a -23.3% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Celldex Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude